Key facts
- Kainova Therapeutics’s last known valuation is $92.0M (May 2022).
- It has raised $113.9M; the latest was Later Stage VC ($23.3M) in Feb 2026.
- Notable investors include Investissement Quebec, Omnes Capital, Turenne Groupe, Schroders Capital, Viva BioInnovator — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Kainova Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Kainova Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kainova Therapeutics
Developer of medical therapeutics designed for the treatment of central nervous system (CNS) diseases and cancer. The company's biopharmaceutical process is dedicated to the discovery and early development of new drug candidates targeting transmembrane receptors, in particular G protein-coupled receptors, enabling healthcare providers with innovative therapeutics that aid in the treatment of cancer.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2001
- Employees
- 38
- Website
- kainovatx.com/
- Ownership
- Privately Held (backing)
Kainova Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kainova Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kainova Therapeutics in its N-PORT filings yet. We sweep new filings monthly.